NewcelX(NASDAQ) NCEL

Current Price$3.76

Market Cap$20.31M

Since IPO (2025)-48%

5 Year-100%

1 Year-83%

1 Month+7%

NewcelX last closing stock price
Metric	Price	Date
Last close	USD 3.80	2026-07-23

NewcelX stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-2.81%	USD 3.91	2026-07-16
1 month	+7.34%	USD 3.54	2026-06-23
3 month	-18.45%	USD 4.66	2026-04-24
Year to date	+100%	USD 1.90	2025-12-31
1 year	-82.73%	USD 22.00	2025-07-23
3 year	-98.86%	USD 331.88	2023-07-24
5 year	-99.68%	USD 1,172.00	2021-07-23
Since inception	-47.87%	USD 7.29	2025-10-31

NewcelX Financials at a Glance

Market Cap

$20.31M

Revenue (TTM)

$0.00

Net Income (TTM)

$144.07K

EPS (TTM)

-$17.34

P/E Ratio

-0.22

Dividend

$0.00

Beta (Volatility)

0.44 (Low)

Dividend

$0.00

Beta (Volatility)

0.44 (Low)

Price

$3.76

Volume

6,082

Open

$3.69

Price

$3.76

Volume

6,082

Open

$3.69

Previous Close

$3.76

Daily Range

$3.65 - $3.76

52-Week Range

$1.83 - $28.03

Estimated Earnings Date

Sep 2, 2026

Dividend

$0.00

Beta (Volatility)

0.44 (Low)

Price

$3.76

Volume

6,082

Open

$3.69

Previous Close

$3.76

Daily Range

$3.65 - $3.76

52-Week Range

$1.83 - $28.03

Estimated Earnings Date

Sep 2, 2026

NCEL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NewcelX

NewcelX Ltd. is a biotechnology firm based in Zurich, Switzerland, established in 2008. The company is focused on developing innovative therapeutic solutions for neurodegenerative and metabolic diseases through cell-based and small-molecule approaches.

Products and Services

Innovative treatments for neurodegenerative diseases
Development of small-molecule therapies
Research and development in metabolic disease solutions

Growth Outlook

Recent quarterly net income of $4.35 million indicates potential profitability
Strong focus on R&D with $476,063 spent in Q4 2025
Market cap of $1.84 million suggests room for growth

Financial Highlights

Trailing twelve months (TTM) revenue of $0 reflects early-stage development
Net income of $4.35 million in Q4 2025 shows positive momentum
Cash and cash equivalents of $2.2 million provide operational stability

NewcelX Ltd. operates in a promising sector, focusing on significant health challenges. The recent financial performance, particularly the positive net income, suggests a potential turning point for the company. With a solid cash position, NewcelX is well-positioned to continue its research and development efforts, which could lead to groundbreaking therapies in the biotechnology field. The company's innovative approach and commitment to addressing complex diseases make it an intriguing option for investors interested in the healthcare sector.

AI Generated • Jul 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Ronen Twito

Website

newcelx.net

Headquarters

Kloten, ZH 8058, CH

NCEL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

41.94%

Return on Capital

-32.53%

Return on Assets

18.57%

Earnings Yield

-4.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$20.31M

Shares Outstanding

5.35M

Volume

6.08K

Avg. Volume

46.40K

Financials (TTM)

Gross Profit

-$5.31K

Operating Income

-$10.26M

EBITDA

-$6.74M

Operating Cash Flow

-$6.34M

Capital Expenditure

-$3.93K

Free Cash Flow

-$6.35M

Cash & ST Invst.

$2.20M

Total Debt

$355.00K

NewcelX Performance Analysis

NewcelX annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

NewcelX sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-06-30	N/A
Q4	2024-12-31	N/A
Q2	2025-06-30	N/A
Q4	2025-12-31	N/A

NewcelX annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -335.23	3.5%
2023	2023-12-31	USD -127.54	-62.0%
2024	2024-12-31	USD -24.32	-80.9%
2025	2025-12-31	USD -2.16	-91.1%

NewcelX sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-06-30	-38.7%
Q4	2024-12-31	-409.9%
Q2	2025-06-30	-6.1%
Q4	2025-12-31	112.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$20.31M

N/A

Market Cap/Employee

$1.85M

N/A

Employees

N/A

Net Income

$4.35M

+95418.0%

EBITDA

-$998.22K

+76.6%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

$2.20M

+145.2%

Total Debt

$355.00K

-78.3%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$355.00K

-78.3%

Return on Assets

18.57%

N/A

Return on Invested Capital

-81.09%

N/A

Free Cash Flow

-$1.98K

+16.9%

Operating Cash Flow

-$1.98K

+17.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CELUCelularity Inc.

CELUCelularity Inc.$0.75-1.32%

SABSSAB Biotherapeutics, Inc.

SABSSAB Biotherapeutics, Inc.$3.51-1.96%

KTTAPasithea Therapeutics Corp.

KTTAPasithea Therapeutics Corp.$0.46-5.25%

NUWENuwellis, Inc.

NUWENuwellis, Inc.$2.05-6.82%

CEROCERo Therapeutics Holdings, Inc.

CEROCERo Therapeutics Holdings, Inc.$0.01-5.66%

BCTXWBriaCell Therapeutics Corp.

BCTXWBriaCell Therapeutics Corp.$0.00-0.00%

BACKIMAC Holdings, Inc.

BACKIMAC Holdings, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

NUNu Holdings

NUNu Holdings$14.09-0.01%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

Questions About NCEL

What is the current price of NewcelX?

NewcelX is trading at $3.76 per share.

What is the 52-week range for NewcelX?

Over the past 52 weeks, NewcelX has traded between $1.83 and $28.03.

How much debt does NewcelX have?

As of the most recent reporting period, NewcelX reported total debt of $355.00K.

How much cash does NewcelX have on hand?

NewcelX reported $2.20M in cash and cash equivalents in its most recent financial results.

What is NewcelX’s dividend yield?

NewcelX does not currently have a dividend yield.

NewcelX(NASDAQ) NCEL

NewcelX Financials at a Glance

NCEL News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About NewcelX

NCEL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

NewcelX Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NCEL

What is the current price of NewcelX?

What is the 52-week range for NewcelX?

How much debt does NewcelX have?

How much cash does NewcelX have on hand?

What is NewcelX’s dividend yield?

Premium Investing Services